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Chronic myeloid leukemia (CML)' is a pluripotent stem cell disorder character-
ized by the presence of the Philadelphia (Ph') chromosome in the leukemic cells of
96% of all CML patients (1). The Ph' chromosome is formed by a reciprocaltranslo-
cation between chromosomes 22 and 9 (2, 3). In this translocation, the c-abloncogene
has moved from chromosome 9 into the breakpoint cluster region (bcr), within the
bcr gene on chromosome 22, resulting in a chimeric bcr-c-abl gene (3, 4). The fused
gene encodes an 8.5-kb chimeric mRNA (5, 6), which is translated into a 210-kD
protein (7) . This P210bcr-abl protein shows tyrosine kinase activity and is uniquely
present in the leukemic cells of CML (and a number of Ph" ALL) patients (8-12).
The breakpoint in the bcr gene occurs either between bcr exon 2 (b2) and 3 (b3),
or alternatively between bcr exon 3 (b3) and 4 (b4). Therefore, in the mature bcr-abl
mRNA, either b2 or b3 is spliced to abl exon a2, which results in two alternative
chimeric P21Obrr-abl proteins, comprising either the b2-a2 or b3-a2 junction (13). As
such, the two different amino acid sequences at the point of the junction represent
unique tumor-specific determinants.
In this study we investigate whether thesejoining determinants are exposed on
the P210b`r-abl molecule in an immunogenic fashion. Our data indicate that the
joining determinants b2-a2 can indeed be recognized by antibodies. The strategy
we used to generate and characterize the anti-b2-a2 antiserum has potential for the
further development of antibodies detecting tumor-specific proteins resulting from
chromosomal rearrangements.
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Materials and Methods
Cell Lines.
￿
K562, LAMA-84, and BV173 are Ph" cell lines derived from patients during
the blast crisis phase of CML. Cells were cultured in RPMI medium supplemented with
7.5%v FCS, 100 ug/ml penicillin, and 60 Wg/ml streptomycin.
Peptide Synthesis, Purification, and Conjugation.
￿
Peptides were synthesized according to the
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solid phase method developed by Merrifield (14) on polystyrene resin (1% crosslinking), using
an automated peptide synthesizer (SAM-2; Biosearch, San Rafael, CA). The reaction se-
quence was performed according to the standard protocol using tertiary-butyl-oxycarbonyl
amino acids with the following side chain protection: lys-2-chlorocarbobenzoxy, glu-benzyl,
gly-benzyl, cys-tertiary-butylmercapto, all commercially available (Fluka A. G. Buchs, Swit-
zerland and Bachem A. G. Bubendorf, Switzerland) . Boc-arg-4-methoxybenzenesulfonyl was
synthesized from Boc-Arg (Fluka A . G. Buchs) and MBS-Cl (Aldrich Chemical Co., Mil-
waukee, WI) according to Nishimura and Fujino (15). Final deblocking and cleavage from
the resin was performed by treatment with trifluorornethanesulfonic acid/Thioanisol/m-Cresol
in trifluoro acetic acid (TEA) for 1 h at 0°C (16), followed by filtration and precipitation from
ether/n-pentane. Cys-containing peptides were treated with 10 equivalent threo-1,4-dimercapto-
2,3-butanechol, pH 8, for 1 h and lyophilized. Gelfiltration of the crude peptide was per-
formed on Sephadex-G15 (Pharmacia Fine Chemicals, Piscataway, NJ) using 5% (vol/vol)
acetic acid as the eluent. For purification by HPLC (Pharmacia Fine Chemicals) a reverse-
phase ultrasphere C18 column, 10 x 250 mm (Beckman Instruments, Inc., Palo Alto, CA),
was used applying a linear gradient from 15% to 40% solution B (0.1% TEA in acetonitrile)
into solution A (0.1% TEA in water), in 15 min at 2.5 ml/min. Amino acid analysis was per-
formed on the hydrolyzed peptide using precolumn derivatisation ofthe amino acids according
toJanssen et al. (17), confirming the expected composition. Peptides were coupled to a carrier
protein (chicken gamma globulin, and BSA) via the terminal cystein residue using m-male-
imidobenzoyl-sulfosuccinimide-ester (18) (MBS) as a bifunctional coupling agent .
Immunizations and Ig Purification.
￿
Flemish rabbits were primed intracutanously with 250
ug protein complex consisting of SP b2-a2 coupled via MBS to CGG, emulsified in an equal
volume of CFA. Rabbits were boosted twice after intervals of 4 wk; the first time with 250
ug of protein in CFA, the second time with the same dose in IFA . 14 d after the last boost
rabbits were bled and sera were collected.
The Igs were purified from the serum by precipitation with 16% Na2SO4 .
Preparation of Anti-bcr Antiserum.
￿
A polyclonal antiserum directed against the NH2 ter-
minus ofthe bcr protein was generated using the bacterial expression vector pEX (19). A 513-
bp Barn HI-Pst I cDNA fragment, derived from the first exon of the bcr gene, was cloned
in the Bam HI and Pst I site of pEX2, thus maintaining the translational reading frame of
the normal bcr protein. The resulting hybrid ß-galactosidase bcr protein was expressed ac-
cording to standard procedures (7) and isolated from the bacteria as follows. The bacteria
were collected and sonicated for 6 min in PBS on ice. After a 5-min centrifugation in an
Eppendorf centrifuge, the pellet was resuspended in PBS and emulsified in an equal volume
of Freund adjuvant. Immunization procedures and Ig purification were as described above.
ELISA.
￿
Binding of antiserum to the synthetic peptides was investigated in a micro ELISA
system as described previously (20). Terasaki trays were coated with 0.1 Ftg antigen/well. Sera
were diluted in PBS supplemented with 0.05% Tween-20. An optimal dilution of donkey
anti-rabbit F(ab)2 fragments conjugated to ß-galactosidase (Amersham Corp., Arlington
Heights, IL) was used as detecting reagent. Binding of antibodies was visualized by incuba-
tion with the fluorogeneic substrate 4-methyl-umbelliferyl-ß-galactopyranoside . Binding is
expressed as arbitrary fluorescence units.
Immunoprecipitation and Protein Kinase Reaction.
￿
Immunoprecipitation and kinase reaction
were carried out according to Chan et al. (21) with some minor modifications. Cells (5 x
106) were washed once in PBS, then lysed for 5 min in 0.5 ml ice-cold lysis buffer (1% Triton
X-100. 0 .05% SDS, 150 mM NaCl, 5 mM EDTA in 10 mM sodium phosphate, pH 7.0),
supplemented with 0.6 mg/ml gelatine, 4 mM PMSF, and 0 .3 mg/ml of each ofthe following
protease inhibitors: aprotinin, trypsin inhibitor, leupeptin, and bestatin (Sigma Chemical
Co., St. Louis, MO). After centrifugation of the lysate in an Eppendorf centrifuge, 5-50 41
of Na2SO4-precipitated Igs were added. Antigen-antibody interaction was allowed for 2 h
at 4°C. Next, 40 wl of a 1 :3 dilution of packed protein A-Sepharose beads (Pharmacia Fine
Chemicals) was added. Beads were collected after a 30-min incubation at 4°C, and washed
twice in lysis buffer without SDS and subsequently washed with 50 MM Tris-HCI, pH 7.0.
The beads were resuspended in 20 wl 20 mM Pipes buffer, pH 7.0 (Sigma Chemical Co.),
supplemented with 20 mM MnC12 and 20 wCi (y-[32p])ATP was added (Amersham Corp.).cys
cys
VAN DENDEREN ET AL.
￿
89
Incubation was allowed for 10 min at 37°C. Beads were then washed twice with lysis buffer
without SDS and boiled in 100 g1 sample buffer. Samples were run at 6% polyacrylamide
gels. Gels were washed in distilled water, dried, and autoradiographed for 30 min, using Fuji
(RX-NIF) films.
RNA Analysis.
￿
RNA was extracted according to the Li/Cl method (22). Samples were
subjected to electrophoresis on formaldehyde 1% agarose gels, transferred to nitrocellulose,
and afterhybridization, exposed for 3 d to Kodak XAR 5 films using intensifying screens.
The oligonucleotides covering the bcr-abl junctions were composed as follows: (b3-a2)5'
TGGATTTAAGCAGAGTTCAA AAGCCCTTCAGCGGCCAGTA 3; (b2-a2)5' GCTGAC-
CATCAATAAGGAAG AAGCCCTTCAGCGGCCAGTA 3'; (primer)5' TACTGGCC 3.
32p_labeled probes were synthesized by extension of the 8-mer primer hybridized to one of
the 40 mers. The primer extension mixture contained 6 mM Tris-HCI (pH 7 .5), 6 mM
MgC12, 6 mM ß-mercaptoethanol, 50 mM NaCl, 30 wCi (a-[32P]) dATP, 30 gCi (a-[32P])
dCTP, 100 mM dGTP, 100 mm,dTTP, 8 ng of the 40-mer, 4 ng of the primer, and 5 U
Klenow polymerase in a total volume of 10 g1. The reaction was performed at room temper-
ature for at least 1 h and stopped by the addition of 90 wl TES (10 mM Tris-HCI, pH 7.5;
5 mM EDTA; 0.1% SDS) followed by removal offree nucleotides on a Sephadex-G50 column.
Ampli,icationofcDNA.
￿
The cDNA amplification was performed using the polymerasechain
reaction. 10 wl of total RNA was ethanol precipitated; washed with 70% ethanol, and dried
in an desiccator. The pellet was dissolved in 9 ul of annealing buffer (250 mM KCI, 10 mM
Tris-HCI, pH 8.3 at 42°C, 1 mM EDTA) and 1 ug of the c-ablprimer 5' GAGCTCGGATC-
CACTGGCCACAAAATCATACAGT 3' was added. The sample was heated for 3 min at
80°C and transferred to a 65°C waterbath to allow annealing of the primer for 1 h. 15 wl
of cDNA buffer (24 mM Tris-HCL, pH 8.3 at 42°C, 16 mM MgC12, 8 mM DDT, 0.4 mM
dNTP) and 5 U ofavian myeloblastosis virus reverse transcriptase were added. This sample
was incubated for 1 h at 42°C. After this step, 1 wg of a bcr primer 5' GAAGAAGTGTTT
CAGAAGCTTCTCCC 3' (from exon b2) was added and 26 cycles of the polymerase chain
reactions were performed directly in a volume of 100 ul, using Taq polymerase.
Results
Synthesis of Peptides Corresponding the bcr-abljunction.
￿
Two peptides were produced
by solid phase synthesis according to Merrifield (14) based on the previously pub-
lished (6) nucleotidesequence ofthe chimeric bcr-ablgene. The peptides were prolonged
with an NH2-terminal cysteine providing a specific coupling site to carrier mol-
ecules.
(a) Synthetic peptide b2-a2 (SP b2-a2) represents the fusion part of b2-a2 P2106`r-abi
and consists of the amino acids:
-ile-asn-lys-glu-g I lu-ala-leu-gln-arg-pro
bcr2
￿
ab12
(b) Synthetic peptide b3-a2 (SP b3-a2) represents the b3-a2 fusion part of b3-a2
P210b`r-abl and consists of the amino acids:
-lys-gln-ser-ser-1 ys-ala-leu-gln-arg-pro
bcr3
￿
ab12
Since the fusion of the bcr and abl genes occurs within a coding triplet (6), the
second glu in SP b2-a2 and the second lys in SP b3-a2 are newly generated by the
translocation process. Thus, both peptides contain newly formed amino acids, share
the c-abl COOH-terminal amino acids and differ at the NH2-bcr terminus.90
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Antibody Binding to Synthetic Peptides.
￿
AntiserumBP-1 was raised againstSP b2-a2.
Here, we show thebindingofBP-1 to the peptidein amicroELISAsystem. Terasaki
trays were coated with SP b2-a2 conjugated to BSA. As a control, Terasaki plates
were coated with BSA-MBSor BSA-MBS-SP b3-a2. As shown in Fig. 1 a, BP-1 bound
to BSA-MBS-SP b2-a2 and, to an equal extent, to BSA-MBS-SP b3-a2 (Fig. 1 b) .
However, binding to BSA-MBS occurred to a much lower extent (Fig. 1 c). This
indicates that antiserum BP-1 contains antibody molecules directed against MBS
and against determinants on both synthetic peptides, most probably on the shared
a2 part of the peptides.
We then investigated the presence of antibodies in the serum directed against the
b2 side of SP b2-a2 by absorption studies (Fig. 1 d). As expected, preincubation
ofantiserum BP-1 with BSA-MBS-SP b2-a2 completely abrogated binding to BSA-
MBS-SP b2-a2. However, absorption with BSA-MBS maintained binding of BP-1
to BSA-MBS-SP b2-a2, suggesting a predominance of anti-SP b2-a2 antibodies in
the serum. Absorption of BP-1 to BSA-MBS-SP b3-a2 showed only partial inhibi-
tion of antibody binding to BSA-MBS-SP b2-a2. This indicates that the majority
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FIGURE 1.
￿
Bindingcharacteristics of antiserum BP-1 to BSA-MBS +/- SPs(a-c) andto BSA-
MBS-SP b2-a2 afterpreabsorption with BSA-MBS +/- SPs(d). (a-c)Binding ofdifferentcon-
centrationsofantiserum BP-1 (0)andnormal rabbit serum(O)to BSA-MBS-SP b2-a2(a), BSA-
MBS-SP b3-a2 (b), and BSA-MBS(c)in a micro ELISA system. Methodswere as describedby
van Soest et al. (20). Binding is expressed as arbitrary fluorescence units (AFUs). (d) Binding
ofantiserumBP-1 to BSA-MBS-SP b2-a2afterpreabsorption with BSA-MBS-SP b2-a2(E), BSA-
MBS-SP b3-a2 (O), and BSA-MBS ("). Binding is expressed as percentage of the binding of
a 1:1,000 dilution of the unabsorbed serum.ofthe anti-SPb2-a2 antibodies in serum BP-1 is directed against theb2 side and/or
the b2-a2 joining region of the peptide.
DNA and RNA Analysis of bcr-ablJoining Regions in CML Cell Lines.
￿
As a source
for native P210bcr-abl, we used three cell lines derived from CML patients in blast
crisis: K562 (23), BV173 (24), and LAMA-84 (25). To determine whether the cell
lines contain b3-a2 P210bcr-abl or b2-a2 P210bcr-ab' we first localized at the DNA and
RNA level the bcr breakpoints and bcr-abljunctions ofthe BV173 and LAMA-84
cells. As previously published, K562 cells contain a breakpoint 3' ofexon b3, and
express a hybrid mRNA in which exon b3 is spliced to exon a2 (6). Southern blot
analysis was performedusing Barn HI and Bgl II restriction enzyme digests to pin-
point to genomic breakpoints on chromosome 22 in BV173 and LAMA-84 (Fig.
2). One extra band was visible using 5' bcr probes (probes aand b), while two rear-
ranged bands were visible in both digests ofLAMA-84 DNA, using a 3' bcr probe.
This indicates that the 3' bcr probe (probe c) detects both the 22q- and the 9q+ hy-
brid fragments in LAMA-84 DNA, which maps the breakpoint within this 1.2-kb
3' Hind III-Bgl II fragment. Thus, LAMA-84 contains a breakpoint in the intron
between exon b3 and b4. In BV173 DNA, only in the Bgl II digest was an extra
band visible, using the 5' bcrprobe. However, using another 5' bcrAvaIprobe (probe
b), two extra bands were seen in the Bam HI digest, apart from the two normal
fragments. Thus, the breakpoint in BV173 is located just 5' of exon b3 within the
Bam HI-Ava I fragment.
To confirm the expected RNA structure surrounding the bcr-abljunction, we hy-
bridized specific oligonucleotides (40-mers) comprising the b3-a2 and b2-a2 junc-
tion sequences to RNA preparations ofthe CML cell lines on Northern blots (Fig.
3). After hybridization, stringent washings were performed, i.e., above the Tin of
the three different 20-mers (b2, b3, and a2). Thus, a signal could only be obtained
when a hybrid bcr-ablmRNA was present. As shown in Fig. 3, the b3-a2 oligomer
hybridizes exclusively to the 8.5-kb hybrid bcr-abl mRNA ofthe K562 and LAMA-
84 cell lines. The b2-a2 oligomer however, only hybridizes to the bcr-abl mRNA of
BV173. These results are in concordance with the DNA breakpoints in the bcr gene
of these cell lines, and strongly indicate that BV173 cells contain b2-a2 P210bcr-
ab',
whereas K562 and LAMA-84 cells both contain b3-a2 P210brr-ab'. Surprisingly, we
do not detect a b2-a2 alternative splice product in K562 RNA, as was previously
found by others (13).
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FIGURE 2.
￿
Genomic break-
points in the bcrof three CML
cell lines, in relation to thebcr
exons and to the bcr-abl fusion
mRNA. A restriction enzyme
map is depicted of the bcr in-
volved in CML. Ber exons
(bl-64) are indicatedby black
boxes belowthe restriction en-
zyme map, andtheprobes used
are shown above it (a, 5' bcr, a
2.2-kb Bgl II-Hind III frag-
ment; b, 5' bcr AvaI, a2-kb Ava
I fragment; c, 3' bcr, a 1.2-kb
Hind III-Bgl II fragment).92
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FIGURE 3 .
￿
Northern blots ofK562, LAMA-84,
and BV173 total RNA preparations . Northern
blots were hybridized to 32p-labeled 40-mers
spanning the b3-a2 or b2-a2 bcr-abljunctions .The
filters were washed in 0.2 x SSC at 60°C. Size
of the mRNA is indicated in kb.
To confirm these observations we decided to use a highly sensitive assay based
on the polymerase chain reaction (PCR) (26) . AcDNA synthesis ofK562 and BV173
RNA was performed, using a c-ablprimer from exon a2 . This cDNA was amplified
using thePCR with bcrand c-ablprimers mapping 345 and 270by apart in the b3-a2
and b2-a2 cDNAs, respectively. As is shown in Fig . 4, the amplified fragment from
K562 RNA is 345 by long and hybridizes to the b3-a2 oligonucleotide, while no
270-bp fragment is detected after hybridization with the b2-a2 oligonucleotide . In
contrast, in BV173 the 270-bp fragment is amplified and hybridizes to the b2-a2
oligonucleotide. These findings strongly argue against a b2-a2 alternative splice in
the K562 cell line we used for the present experiments .
Immunoprecipitation ofP210bcr- ablfrom CML Cell Lines.
￿
Binding of antiserum BP-1
to both b2-a2 P210bcr-a" and b3-a2 P210b`r-abl was tested by immunoprecipitation
and autophosphorylation ofthe proteins . Fig . 5 shows a clear precipitation of b2-a2
P210bcr-abl from BV173 cells (lane 2) . Strikingly, b3-a2 P210ber-abl from LAMA-84
and K562 cells was not precipitated by BP-1 (Fig . 5, lanes 4 and 6) . To show that
b3-a2 P210bar-abl indeed is present in our K562 and LAMA-84 cells, we precipitated
these molecules with a polyclonal antiserum directed against the NH2 terminus of
the bcr protein (Fig . 6, lanes 2 and 4) . Since P210bcr-abl is clearly precipitated, we
conclude that antiserum BP-1 recognizes an antigenic determinant on b2-a2
P21Obcr-abl which is not expressed on b3-a2 P210bcr-abl .VAN DENDEREN ET AL .
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FIGURE 4 .
￿
Amplification ofthe bcr-abl junction
from K562 and BV173 cDNA. 2% agarose gels
were run with 257o of the yield of the final PCR
reactions. A was hybridization to the b3-a2 40-
mer andBwas hybridized to the b2-a2 40-mer.
Hybridization and washing conditions were as
in Fig . 3 .
To analyze the specificity of the binding of BP-1 to P21obcr-abi in more detail, pep-
tide blocking studies were performed, either with unconjugated SP b2-a2 or with
SP b3-a2 . Fig . 3 shows that immunoprecipitation ofb2-a2 P210 was prevented after
incubation of BP-1 with thecognatepeptide b2-a2 (Fig . 5, lane 7) . In contrast, incu-
bation with SP b3-a2 (Fig . 5, lane 8) had no effect on immunoprecipitation . This
indicates that precipitation of b2-a2 P210bcr-ab i could not be caused by antibodies
directed against the a2 part of P210bcr-abi, since those antibodies were removed by
absorption with the b3-a2 peptide.
Discussion
P210bcr-abi can be considered as a highly tumor-specific protein forCML (8-11) .
In addition, the molecule is also detected in 10-25% of Ph'+ ALL patients (12) . It
has been suggested that these patients have a CML blast crisis without or with a
very short, preceding chronic phase (27).
The tumor-specific character of P210b`r-abi is different from that of other previ-
ously described tumor-specific or tumor-associated antigens . Aproblem occurring
for many tumor-associated antigens is that they are not only produced by tumorANTIBODY RECOGNITION OF bcr-abl
FIGURE 5 .
￿
Immunoprecipita-
tion analysis of the specificity of
antiserum BP-1 . BV173, K562,
andLAMA-84 cells were lysed
and immunoprecipitated with
10 g1 Na2SO4 precipitated
normal rabbit serum (lanes 1,
3, and 5) and with 10 ul
Na2SO4 precipitated serum
BP-l (lanes 2, 4, and 6) . (Lane
7and 8) Immunoprecipitation
analysis of BV173 cells with
serum BP-1 after addition of
0.25mM SP b2-a2 (lane 7) and
0.25mM SP b3-a2 (lane 8) . Im-
munoprecipitation and kinase
reaction were carried out ac-
cording to Chan et al . (21) .
FIGURE 6 .
￿
Immunoprecipitation analysis of K562,
LAMA-84, andBV 173 cells with a polyclonal serum
directed against the NH2 terminus of the bcr pro-
tein . The cells were lysed and precipitated with 25
wl Na2SO4 precipitated normal rabbit serum (lanes
1, 3, and 5) and with 25 gl Na2SO4 precipitated
anti-bcr antiserum (lanes 2, 4, and 6) .VAN DENDEREN ET AL.
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cells, but also, although in a lower degree, by normal cells (28). The P97 antigen,
for example, is highly associated with malignant melanoma, but is also expressed
on normal tissue (29). Other antigens, such as the TAG-72 antigen (30), are not
specific for one particular tumor but are expressed on a variety of tumors. In con-
trast, P210b`r-ab' can only be produced by cells carrying the CML-specific bcr-abl
translocation and is therefore, by definition, a tumor-specific antigen. P210bcr-abl
however, is composed ofthenormal bcr and abl proteins, whichare, as such, non-tumor-
specific determinants on the fusion protein. Theoretically, the only tumor-specific
determinant on the P210b`r-ab' molecule is formed just by the joining between bcr
and abl.
In this report we show the possibility to produce a polyclonal antiserum recog-
nizing the bcr-abljoining region by using a synthetic peptide corresponding the b2-
a2 junction as an immunogen. Molecular studies revealing the nucleotide sequence
at this junction (6) made this direct approach possible. As such, our approach differs
principally from other strategies meant for the production of tumor-specific anti-
bodies, where tumor cells, tumor cell membranes, or purified proteins were used
as immunogens (30-32).
The peptide we synthesized consisted of four amino acids derived from b2 and
five amino acids derived from a2. Between these amino acids, one amino acid is
located, which is newly generated by the Philadelphia translocation. Thepolyclonal
antiserumwe obtained afterimmunization with the peptide reactedin avery specific
waywith the native b2-a2 P21obcr-abl molecule using the protein kinase assay. In con-
trast, b3-a2 P21obcr-abl was not recognized by BP-1 in this assay. Our ELISA data
indicated, however, that BP-1 reacted with different parts ofthe peptide; the a2 part
as well as the b2 and/or b2-a2junction were recognized by BP-1. Since no precipita-
tion of b3-a2 P21obcr-abl was detected, the b2 and a2 amino acids were not recog-
nized in the native b3-a2 P21obcr-abl molecules. We conclude, therefore, that the in-
dividual b2 and a2 determinants, as exposed on the peptide, are hidden within the
tertiary structure of the native b3-a2 P210bcr-ab' and are inaccessible for anti-b2 and
anti-a2 antibodies.
We also showed that b2-a2 P210b`r-abl was not precipitated by antibody molecules
directed against a2 sequences, because after removing anti-a2 reactivity from BP-1
by absorption, b2-a2 P21obcr-abl was still precipitated. This leaves us with the con-
clusion that under the present experimental conditions, b2-a2 P210b`r-abl from
BV173 cells is precipitated by antibodies recognizing the b2-a2joining region itself
or by antibodies that recognize newly created tertiary b2 or a2 determinants intro-
duced by the bcr-abl joining region.
Furthermore, the observation that no b2-a2 P210bcr-ab' is precipitated by BP-1
from the K562 cells was an extra confirmation of our molecular data, i.e., the ab-
sence of a b2-a2 alternative splice in the K562 cell line we used.
In summary, we have shown that breakpoint-specific DNA-encoded sequences are
exposed on P210bcr-ab' molecules and that, under the present experimental condi-
tions, such sequences can be visualized at the protein level by antibodies generated
through the use of synthetic peptides encoded by these sequences as immunogens.
Obviously, antibodies obtained in this way may furtheraid in the clinical diagnosis
of CML and in the distinction of the various malignant disorders where chromo-96
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some rearrangements are involved . Studies to detect individual tumor cells using
immunohistochemical techniques are now in progress.
Summary
Chronic myeloid leukemia (CML) is characterized by the presence of a 210-kD
protein (P210bcr-abl) in the cytoplasm of leukemic cells, generated by the reciprocal
translocation between chromosome 9 and chromosome 22. Due to this transloca-
tion, the abl oncogene is coupled to the bcr gene, forming a new determinant in this
protein encoded by the bcr-abl joining region. In the joining region itself, either the
bcr exon 2 is coupled to the abl exon 2 (b2-a2), or the bcr exon 3 is coupled to the
abl exon 2 (b3-a2). Thus, thesejoining regions form by definition new tumor-specific
determinants in the respective chimeric P21obcr-ab molecules.
This paper addresses the question as to whether these tumor-specificjoining regions
are exposed on the P21obcr-abl molecule in such a way that antibodies can be gener-
ated to detect these sites. To test this possibility a polyclonal antiserum, termed BP-1,
was raised against a synthetic peptide representative for the ó2-a2 joining region.
The reactivity of BP-1 was analyzed in an ELISA system on various synthetic pep-
tides. Peptide inhibition studies showed the presence of antibodies to different parts
of the b2-a2 peptide in the polyvalent antiserum.
The reactivity of BP-1 was then tested with native P21obcr-abl molecules in var-
ious CML cell lines (K562, LAMA-84, and BV173) using a protein kinase assay.
In this context, the bcr-abljunctions were first analyzed at the DNA and RNA level.
The present study indicates that BP-1 specifically recognizes the b2-a2 junction in
native P21Obcr-abl. Furthermore, BP-1 clearly discriminates between ó2-a2 P2lobcr-abl
and b3-a2 P2106cr-abl. We conclude that the tumor-specific b2-a2 joining region is
antigenically exposed on the native P2106cr-abl molecule.
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